Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | 5M | 4M | 5M | 4M |
| Gross Profit | 200K | -112K | -2M | -5M |
| Operating Income | -13M | -14M | -16M | -11M |
| EBITDA | -13M | -17M | -15M | -11M |
| Net Income | -27M | -21M | -16M | -11M |
| EPS (Diluted) | — | — | — | — |
Healthcare
Live Price
Offline$0.182
-4.71% today
Window Change
-96.38%
Window
Aug 29, 2025 → Jun 16, 2026
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 199 bars · Aug 29, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Picard Medical, Inc. (PMI) is a fund with a market cap of $680.00M and listed on AMEX. The fund last traded around $0.18 and down 96.4% across the available one-year price window (Aug 29, 2025 → Jun 16, 2026). Valuation already assumes a fairly strong business story at price/sales 138.3. Stock Foundry combines PMI price history, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PMI
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PMI Max Drawdown
-98.94%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PMI and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$4.1M
-18.4% YoY
FY Net Income
-$11.2M
+28.3% YoY
Free Cash Flow
-$10.8M
-1.0% YoY
Revenue Growth
+12.5%
EPS Growth
-12.1%
Gross Margin
4.0%
Net Margin
-561.9%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | 5M | 4M | 5M | 4M |
| Gross Profit | 200K | -112K | -2M | -5M |
| Operating Income | -13M | -14M | -16M | -11M |
| EBITDA | -13M | -17M | -15M | -11M |
| Net Income | -27M | -21M | -16M | -11M |
| EPS (Diluted) | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & Equivalents | 7M | 96K | 244K | 152K |
| Total Assets | 23M | 12M | 11M | 15M |
| Total Liabilities | 19M | 36M | 15M | 4M |
| Shareholder Equity | 4M | -24M | -4M | 11M |
| Total Debt | 7M | 21M | 9M | 2M |
| Net Debt | -476K | 21M | 9M | 2M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
11M
-0.8% YoY
Capital Expenditures
29K
-314.3% YoY
Free Cash Flow
11M
-1.0% YoY
Key ratios
Gross Margin
4.0%
Operating Margin
-258.7%
Net Margin
-561.9%
ROE
217.5%
Debt / Equity
1.84x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.